[{"id":"61d56240-acd7-4036-be44-40ad727ab77a","acronym":"A051701","url":"https://clinicaltrials.gov/study/NCT03984448","created_at":"2021-01-18T19:35:47.901Z","updated_at":"2025-02-25T15:11:12.787Z","phase":"Phase 2/3","brief_title":"Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas","source_id_and_acronym":"NCT03984448 - A051701","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MYC • BCL2 • BCL6","pipe":" | ","alterations":" BCL2 expression • MYC expression • MYC translocation • MYC negative • BCL2 translocation","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • MYC expression • MYC translocation • MYC negative • BCL2 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 363","initiation":"Initiation: 10/22/2019","start_date":" 10/22/2019","primary_txt":" Primary completion: 04/01/2028","primary_completion_date":" 04/01/2028","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2025-02-13"},{"id":"2dd784c3-2556-4e8f-858c-e43a2f1be9da","acronym":"realMIND","url":"https://clinicaltrials.gov/study/NCT04981795","created_at":"2021-07-29T14:53:08.563Z","updated_at":"2024-07-02T16:34:26.241Z","phase":"","brief_title":"realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL","source_id_and_acronym":"NCT04981795 - realMIND","lead_sponsor":"Incyte Corporation","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 translocation • BCL2 translocation","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 translocation • BCL2 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Monjuvi (tafasitamab-cxix)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 09/20/2021","start_date":" 09/20/2021","primary_txt":" Primary completion: 10/31/2025","primary_completion_date":" 10/31/2025","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2024-06-13"},{"id":"145fc814-0727-4779-a567-acfbf6720fd9","acronym":"SAKK 38/23","url":"https://clinicaltrials.gov/study/NCT06090162","created_at":"2023-10-19T17:12:55.572Z","updated_at":"2024-07-02T16:35:14.707Z","phase":"","brief_title":"LIBERTY: Liquid Biopsy to Diagnose and Monitor CNS Involvement in High-risk B Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT06090162 - SAKK 38/23","lead_sponsor":"Swiss Group for Clinical Cancer Research","biomarkers":" TP53 • MYC • BCL2 • BCL6","pipe":" | ","alterations":" TP53 mutation • MYC translocation • BCL2 translocation","tags":["TP53 • MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • MYC translocation • BCL2 translocation"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 03/12/2024","start_date":" 03/12/2024","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-03-15"},{"id":"300dc214-2f53-46f4-88db-099cbeecb27f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05755087","created_at":"2023-03-06T15:01:37.165Z","updated_at":"2024-07-02T16:35:24.905Z","phase":"Phase 1","brief_title":"Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma","source_id_and_acronym":"NCT05755087","lead_sponsor":"Lapo Alinari","biomarkers":" MYC • BCL2 • BCL6","pipe":" | ","alterations":" BCL2 expression • MYC expression • MYC translocation • MYC translocation + BCL2 translocation • BCL2 translocation","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • MYC expression • MYC translocation • MYC translocation + BCL2 translocation • BCL2 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tegavivint (BC2059)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 03/06/2023","start_date":" 03/06/2023","primary_txt":" Primary completion: 03/05/2027","primary_completion_date":" 03/05/2027","study_txt":" Completion: 03/05/2027","study_completion_date":" 03/05/2027","last_update_posted":"2023-12-29"},{"id":"1e9a0fed-aa81-40d5-835d-c166a3f33f32","acronym":"","url":"https://clinicaltrials.gov/study/NCT06120166","created_at":"2023-11-07T16:14:25.295Z","updated_at":"2024-07-02T16:35:30.192Z","phase":"Phase 1","brief_title":"Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research","source_id_and_acronym":"NCT06120166","lead_sponsor":"He Huang","biomarkers":" MYC • BCL2 • CD19 • BCL6 • IL6","pipe":" | ","alterations":" CD19 expression • BCL2 translocation","tags":["MYC • BCL2 • CD19 • BCL6 • IL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression • BCL2 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Meta10-19"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 11/20/2023","start_date":" 11/20/2023","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 04/05/2026","study_completion_date":" 04/05/2026","last_update_posted":"2023-11-07"},{"id":"3e8d61ce-5436-4030-a690-3833bf9a750d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01742988","created_at":"2021-01-18T07:38:21.868Z","updated_at":"2024-07-02T16:36:30.660Z","phase":"Phase 1","brief_title":"Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma","source_id_and_acronym":"NCT01742988","lead_sponsor":"Curis, Inc.","biomarkers":" MYC • BCL2 • BCL6 • CREBBP","pipe":" | ","alterations":" MYC overexpression • BCL6 rearrangement • MYC translocation • BCL2 rearrangement • BCL6 translocation • BCL2 translocation","tags":["MYC • BCL2 • BCL6 • CREBBP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC overexpression • BCL6 rearrangement • MYC translocation • BCL2 rearrangement • BCL6 translocation • BCL2 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • fimepinostat (CUDC-907)"],"overall_status":"Completed","enrollment":" Enrollment 106","initiation":"Initiation: 12/01/2012","start_date":" 12/01/2012","primary_txt":" Primary completion: 10/09/2020","primary_completion_date":" 10/09/2020","study_txt":" Completion: 10/09/2020","study_completion_date":" 10/09/2020","last_update_posted":"2021-05-06"}]